We hoped industry layoffs would relent in 2024. That's not what happened. | As always, if you know of layoffs occurring at a ...

Shocking profiteering in healthcare system continues to harm patients nationwide. • The 2024 Shkreli Awards highlighted the 10 most egregious examples of healthcare profiteering and dysfunction, ...

Bio-Thera Solutions Inc. announced that it has partnered with Tabuk Pharmaceutical Manufacturing Company to commercialize BAT2206, ...

The FDA wrapped up 2024 with 50 new drug approvals, clearing a wave of long-awaited treatments. Meanwhile, Transcarent will ...

If innovative cancer therapies were the top launches to watch in 2024, this year’s high-profile biopharma debuts is slated to ...

The health benefits of time-restricted eating go beyond weight loss and may be most prominent in patients already with ...

Drug discovery is a key area for AI, given the speed at which models trained on massive datasets can tackle a variety of tasks. Last year, Nvidia said it was doubling down on AI-powered drug discovery ...

Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, today announced the release of the twelfth annual Drugs to Watch™ report, a trusted guide to the therapies poised to ...

In a report released yesterday, Srikripa Devarakonda from Truist Financial maintained a Hold rating on Amgen (AMGN – Research Report), with a ...

Truist lowered the firm’s price target on Amgen (AMGN) to $298 from $333 and keeps a Hold rating on the shares as part of a broader research ...

Amgen Inc. closed $84.79 short of its 52-week high ($346.85), which the company achieved on July 25th.

Amgen Inc (AMGN) stock saw a decline, ending the day at $258.59 which represents a decrease of $-2.63 or -1.01% from the prior close of $261.22. The stock opened at $259.05 and touched a low of ...